Project Grant R01NS137852
- The National Institute of Neurological Disorders and Stroke awarded the University of Colorado a Project Grant totaling $184,506 on August 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This two-year award, with an ultimate completion date of July 31, 2027, supports research investigating the dual roles of amyloid beta (AB) in central nervous system neuropathogenesis associated with HIV-Associated Neurocognitive Disorder...
- The Scintillon Institute received a $1,025,015 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 11, 2025, with completion targeted for July 31, 2027. The award funds development of a next-generation preclinical NeuroHIV model to advance understanding of how Human Immunodeficiency Virus (HIV-1) affects the central nervous system...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Wistar Institute of Anatomy and Biology a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 5, 2026, with a completion date of January 31, 2028. This award supports research aimed at defining the single-cell epigenetic landscape of the HIV-1 reservoir to enable more effective latency reversal strategies. The project addresses a critical gap in HIV cure...
- Federal Project Grant Award Summary Temple University-Of The Commonwealth System Of Higher Education received a Project Grant award of $435,875 from the NIH Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 15, 2025, with a completion date of July 31, 2027. The award funds research investigating the role of circular RNAs (circRNAs) derived from the amyloid precursor protein (APP) gene in beta-amyloid formation and HIV-1-associated...
- The BRAIN-FRAME (Brain-Focused Research on Antiretrovirals and Methamphetamine) project grant, awarded by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2.475 million in federal funding to UC San Diego to conduct a multidisciplinary 52-week research initiative addressing HIV treatment and methamphetamine use disorder. The project integrates implementation science, pharmacology, virology, immunology, and neuroscience...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of North Carolina at Chapel Hill $194,375.00 under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) for a two-year project period from August 1, 2025, through July 31, 2027. This Project Grant funds research investigating the relationship between brain structure and function, central nervous system (CNS) HIV persistence,...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $698,390 to the Regents of the University of California at Riverside on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This Project Grant supports a five-year research initiative (completion date June 30, 2030) focused on harnessing innate immunity to control the neuroinflammatory human immunodeficiency...
- Federal Grant Award Summary The University of Pittsburgh received a $437,250 Project Grant award from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 15, 2025 through July 31, 2027. This R21 award funds research investigating CD4 T Helper 1 (TH1) cells and T Central Memory (TCM) cells as modulators of neuroinflammation in the context of HIV-Associated Neurocognitive Disorders (HAND). The research will deliver...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $1.1 million Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective May 1, 2026 through January 31, 2031. This research grant supports a five-year investigation into the effects of broadly neutralizing antibodies (BNAbs) on neuroinflammation and central nervous system (CNS) persistence in simian immunodeficiency virus (SIV)-infected antiretroviral...
- Federal Grant Award Summary Rush University Medical Center received a $1.52 million Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242), awarded April 1, 2026, with a completion date of March 31, 2028. This research initiative develops a human-mouse chimera model to investigate the dynamics of HIV infection in the brain and its neurological consequences. The project generates scientific knowledge regarding how HIV-infected...
EPIGENETIC PROFILING OF HIV-ASSOCIATED NEUROINFLAMMATION AND PROVIRAL EXPRESSION IN THE BRAIN - ABSTRACT BACKGROUND: HIV INFECTION IN THE BRAIN OCCURS EARLY AFTER TRANSMISSION AND LEADS TO CHRONIC NEUROINFLAMMATION. ALTHOUGH MODERN ANTIRETROVIRAL THERAPY (ART) CONTROLS VIRAL REPLICATION, THERE IS NO CURE FOR HIV, AND SUCCESSFUL CONTROL OF VIRAL REPLICATION HAS NOT COMPLETELY AMELIORATED INFLAMMATION AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND). MICROGLIA PLAY A CENTRAL ROLE IN OTHER NEURODEGENERATIVE DISORDERS AND ARE THE LIKELY PRIMARY RESERVOIR FOR HIV IN THE BRAIN, BUT LITTLE ELSE IS KNOWN ABOUT THE INFLAMMATORY CHARACTER ASSOCIATED WITH HAND. ADDITIONALLY, THE INFLAMMATORY INCITEMENT ASSOCIATED WITH HIV IS POTENTIALLY DETERMINED BY ITS EXPRESSION OF VIRAL PROTEINS, DICTATED BY THE EPIGENETIC MICROENVIRONMENT OF THE PROVIRUS, WHICH IS POORLY CHARACTERIZED. RECENTLY, THE NURR1 RECEPTOR WAS DESCRIBED AS AN IMPORTANT MEDIATOR OF HIV-1 SILENCING IN THE CONTEXT OF MICROGLIA IN VITRO, MAKING IT A PROSPECTIVE FOCAL POINT FOR FURTHER STUDIES IN BRAIN TISSUE. STUDY COHORT: WE WILL LEVERAGE THE UNIQUE LAST GIFT RAPID AUTOPSY COHORT, WHICH ALLOWS US TO PRESERVE CELLULAR INTEGRITY AND NUCLEIC ACIDS IN PRECIOUS TISSUE SAMPLES COLLECTED FROM PWH. WE WILL SELECT FRONTAL CORTEX AND BASAL GANGLIA FROM 15 LAST GIFT PARTICIPANTS TO ANALYZE FOR THIS PROPOSAL. OUR GOAL: USING POWERFUL SINGLE CELL SEQUENCING TECHNIQUES, WE WILL CHARACTERIZE THE EPIGENETIC REGULATORS OF THE HIV PROVIRUS IN BRAIN MYELOID CELLS FROM 15 PWH USING NOVEL EPIGENETIC ENRICHMENT TECHNIQUES AND ASSIMILATED DATA ON INTEGRATION SITES AND THE FULL-LENGTH PROVIRAL SEQUENCE GENERATED AS PART OF THE LAST GIFT PROJECT (AIM 1). NEXT, USING BRAIN MYELOID CELLS ISOLATED FROM A SUBSET OF THE PARTICIPANTS (N=6), WE WILL FURTHER EXPLORE THE MECHANISTIC FRAMEWORK OF THE HIV PROVIRUS IN MICROGLIA THROUGH MANIPULATION OF THE PROVIRAL EPIGENETIC PROFILE USING IN VITRO NURR1 AGONISTS AND EPIGENETIC MODULATORS (AIM 2). FINALLY, WE WILL USE SINGLE CELL TECHNIQUES TO EXAMINE THE EPIGENETIC AND TRANSCRIPTOMIC PROFILE OF THE INFLAMMATORY MILIEU IN THE BRAINS OF PWH ON SUPPRESSIVE ART AND CORRELATE THEM WITH PROVIRAL LOAD AND CELL-ASSOCIATED VIRAL RNA (AIM 3). HOW WILL WE ADVANCE THE FIELD? THE EPIGENETIC CHARACTERISTICS OF THE HIV PROVIRUS HAVE NOT BEEN EXAMINED IN THE BRAINS OF PEOPLE WITH HIV (PWH). MOST EVALUATION OF PROVIRAL EPIGENETICS HAS BEEN FOCUSED UPON CD4+ T CELLS, BUT THUS FAR FEW HAVE EXAMINED EPIGENETIC MECHANISMS OF PROVIRAL REACTIVATION IN MICROGLIA FROM PWH, AND NONE HAVE BEEN ABLE TO DEFINE THESE MECHANISMS THOROUGHLY IN TISSUE SAMPLES OR CELLS ISOLATED FROM BRAINS OF PWH. THEREFORE, THIS PROPOSAL WILL ADVANCE OUR UNDERSTANDING OF HIV PERSISTENCE IN THE BRAIN ON MULTIPLE FRONTS. ADDITIONALLY, THE INFLAMMATORY PATHOGENESIS OF NCI IN HIV INFECTION IS POORLY CHARACTERIZED, BUT OUR PROPOSAL WOULD NOT ONLY ALLOW DEFINITION OF THE IMMUNE CELL CHARACTER IN THE BRAINS OF PWH, BUT ALSO THE EPIGENETIC AND TRANSCRIPTOMIC MECHANISMS AT PLAY IN ALL CELL TYPES, INCLUDING NEURONS AND ASTROCYTES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $788.6k | 7/3/25 | ||
| Not listed | $818.9k | 7/10/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
707289S | University Of North Carolina At Chapel Hill | Project Grant R01NS137852 | $371.4k | 9/29/25 |